Robert M. Hoffman completed his PhD in Biology at Harvard University in 1971. His post-doctoral training was at Massachusetts General Hospital, Boston and Institutes of Bioorganic Chemistry and Molecular Biology, Moscow, Russia. He has been a member of the University of California San Diego School of Medicine faculty since 1979 and is currently Professor of Surgery. He began his research career in 1965 and in 1984 he founded AntiCancer, Inc. Dr Hoffman has been a pioneer on tumor-targeting bacteria; patient-derived orthotopic xenograft (PDOX) mouse models of cancer; recombinant protein-based cancer drugs and diagnostics; as well as hair follicle-associated-pluripotent (HAP) stem cells. Dr Hoffman's research demonstrated the elevated use of methionine by all cancer types, which is called the Hoffman-effect, analogous to the Warburg-effect of the elevated use of glucose in cancer. Dr Hoffman has published approximately 1,000 scientific papers which have been cited approximately 42,000 times with an h-index of approximately 102. In 2016, Dr Hoffman was awarded the Sun Lee Prize from the International Society for Experimental Microsurgery.